Cover Image
市場調查報告書

AbGenomics International, Inc.的產品平台分析

AbGenomics International, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253722
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
AbGenomics International, Inc.的產品平台分析 AbGenomics International, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 30 Pages
簡介

AbGenomics International, Inc.是總公司在美國的生物製藥企業,進行著免疫相關的發炎疾病及癌症治療用的抗體開發。提供自體免疫疾病、胰臟癌症、胃癌、大腸癌症、卵巢癌症、肺癌症及其他固態腫瘤的治療用抗體醫藥品。

本報告提供AbGenomics International, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

AbGenomics International, Inc. 的基本資料

  • AbGenomics International, Inc. 概要
  • 主要資訊
  • 企業資料

AbGenomics International, Inc. :R&D概要

  • 主要的治療範圍

AbGenomics International, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

AbGenomics International, Inc. :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的開發中產品/聯合治療模式
    • 第一階段的開發中產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

AbGenomics International, Inc. :藥物簡介

  • AbGn-168H
  • AbGn-7 15
  • AbGn-107
  • AbGn-108
  • AbGn-109
  • AbGn-110
  • AbGn-122 20

AbGenomics International, Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AbGenomics International, Inc. :最近的開發平台資訊

AbGenomics International, Inc. :開發休止的計劃

AbGenomics International, Inc. :開發中止的開發中產品

AbGenomics International, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06894CDB

Global Markets Direct's, 'AbGenomics International, Inc. - Product Pipeline Review - 2015', provides an overview of the AbGenomics International, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AbGenomics International, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AbGenomics International, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AbGenomics International, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AbGenomics International, Inc.'s pipeline products

Reasons to buy

  • Evaluate AbGenomics International, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AbGenomics International, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AbGenomics International, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AbGenomics International, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AbGenomics International, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AbGenomics International, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AbGenomics International, Inc. Snapshot
    • AbGenomics International, Inc. Overview
    • Key Information
    • Key Facts
  • AbGenomics International, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • AbGenomics International, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AbGenomics International, Inc. - Pipeline Products Glance
    • AbGenomics International, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • AbGenomics International, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • AbGenomics International, Inc. - Drug Profiles
    • AbGn-168H
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AbGn-7 15
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AbGn-107
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AbGn-108
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AbGn-109
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AbGn-110
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AbGn-122 20
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AbGenomics International, Inc. - Pipeline Analysis
    • AbGenomics International, Inc. - Pipeline Products by Target
    • AbGenomics International, Inc. - Pipeline Products by Route of Administration
    • AbGenomics International, Inc. - Pipeline Products by Molecule Type
    • AbGenomics International, Inc. - Pipeline Products by Mechanism of Action
  • AbGenomics International, Inc. - Recent Pipeline Updates
  • AbGenomics International, Inc. - Dormant Projects
  • AbGenomics International, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AbGenomics International, Inc., Key Information
  • AbGenomics International, Inc., Key Facts
  • AbGenomics International, Inc. - Pipeline by Indication, 2015
  • AbGenomics International, Inc. - Pipeline by Stage of Development, 2015
  • AbGenomics International, Inc. - Monotherapy Products in Pipeline, 2015
  • AbGenomics International, Inc. - Phase II, 2015
  • AbGenomics International, Inc. - Phase I, 2015
  • AbGenomics International, Inc. - Preclinical, 2015
  • AbGenomics International, Inc. - Pipeline by Target, 2015
  • AbGenomics International, Inc. - Pipeline by Route of Administration, 2015
  • AbGenomics International, Inc. - Pipeline by Molecule Type, 2015
  • AbGenomics International, Inc. - Pipeline Products by Mechanism of Action, 2015
  • AbGenomics International, Inc. - Recent Pipeline Updates, 2015
  • AbGenomics International, Inc. - Dormant Developmental Projects,2015
  • AbGenomics International, Inc., Other Locations

List of Figures

  • AbGenomics International, Inc. - Pipeline by Top 10 Indication, 2015
  • AbGenomics International, Inc. - Pipeline by Stage of Development, 2015
  • AbGenomics International, Inc. - Monotherapy Products in Pipeline, 2015
  • AbGenomics International, Inc. - Pipeline by Top 10 Target, 2015
  • AbGenomics International, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • AbGenomics International, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • AbGenomics International, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top